Infertility affects one in six people of reproductive age worldwide, yet it remains one of the most overlooked public health challenges of our time. For decades, millions of individuals and couples have navigated this journey in silence, carrying grief, stigma, financial strain, and deep uncertainty about their reproductive futures. Despite its prevalence, infertility has rarely been treated as a global health priority.

That changed this year when the World Health Organization released its first-ever global guideline on the prevention, diagnosis, and treatment of infertility.

This long-awaited document does more than provide clinical recommendations; it reframes infertility as a matter of health equity, human rights, and social justice.

As a reproductive endocrinologist who has spent over two decades caring for a multicultural community of women and families, I see this moment not just as a scientific milestone, but as a moral one. And as the author of the forthcoming book The Quest for Fertility, which explores fertility through biological, social, cultural, and environmental lenses, the WHO’s global guidance feels both timely and profoundly validating.

Infertility is not just a clinical condition, it is a global equity issue

The WHO guideline acknowledges realities clinicians have observed for years:

• The emotional toll of infertility is comparable to that of cancer or heart disease.
• Financial barriers continue to push people toward unsafe or unproven treatments.
• Cultural stigma in many parts of the world leads to isolation, marital stress, or even partner violence.
• Health systems often lack trained providers, standardized pathways, or equitable access.

By explicitly naming infertility as a global public health concern, the WHO sends a powerful message: Fertility care is not a luxury. It is a component of the right to health.

This matters especially for women in cultures where motherhood is tightly tied to identity, value, or social acceptance. I have cared for patients who delayed seeking help for years because they feared being blamed, shamed, or silenced. A global guideline legitimizes their experience and gives them, and their clinicians, language and validation.

The guideline’s strengths: equity, practicality, and evidence

One of the guideline’s greatest strengths is its practicality. The WHO recognizes the wide disparities in resources across countries and offers tiered recommendations based on feasibility and availability. For example, it supports using 2D ultrasound instead of more advanced imaging in low-resource settings, with clear follow-up steps to maintain diagnostic accuracy.

This approach acknowledges what clinicians in real-world environments already know: Evidence-based care must also be context-based care.

The guideline also emphasizes:

• Progressive, stepwise diagnostic pathways
• Inclusion of male-factor infertility
• Prevention strategies involving weight, diet, infections, and tobacco cessation
• Psychosocial support for individuals and couples
• Integration of fertility services into primary care and national health systems

These principles reflect a broader, more compassionate understanding of infertility, one that aligns closely with the holistic approach many of us have advocated for throughout our careers.

Where the guideline falls short, and where the future must go

While comprehensive, the guideline is not meant to capture the depth of lived experience. There are areas that demand continued exploration:

1. The cultural dimensions of infertility. The WHO acknowledges stigma but does not fully address how cultural norms, faith traditions, gender expectations, and family dynamics shape fertility experiences. These pressures are often the primary drivers of emotional distress, especially for women.

2. Environmental and epigenetic factors. The guideline mentions prevention but does not dive into the accelerating science of the exposome, how air pollution, endocrine disruptors, microplastics, and modern toxins impact reproductive health. Nor does it fully address emerging research on epigenetic imprinting and generational effects.

3. Emotional and relational trauma. Algorithms can guide diagnosis but cannot soothe the fear of another negative test. They cannot address the strain infertility places on marriages, identities, or mental health. These are gaps clinicians must continue to fill with empathy and patient-centered care.

4. Global access and cost barriers. Acknowledging inequity is only the first step. The next will require governments, payers, and health systems to invest in subsidized, standardized, ethically delivered fertility services.

A global guideline is only as powerful as our willingness to act on it.

The WHO’s document marks a turning point, but it is only the beginning. Implementation will require investment, collaboration, and courageous conversation. It will require clinicians to advocate for fertility as part of general health, not a luxury offering on the periphery of medicine. It will require societies to challenge stigma, and policymakers to build pathways that are affordable, accessible, and respectful.

This is where clinicians, educators, and advocates (myself included) must step in.

I am more convinced than ever that the world is ready for a broader, deeper conversation about fertility: one that blends science with culture, equity with empowerment, and medicine with humanity.

The WHO has given us the framework. Now it is up to all of us to translate that framework into understanding, action, and compassionate, evidence-based care for every person who desires the chance to build a family.

Infertility is universal. Access to care should be too.

Oluyemisi (Yemi) Famuyiwa is a renowned fertility specialist and founder, Montgomery Fertility Center, committed to guiding individuals and couples on their path to parenthood with personalized care. With a background in obstetrics and gynecology from Georgetown University Hospital and reproductive endocrinology and infertility from the National Institutes of Health, she offers cutting-edge treatments like IVF and genetic testing. She can be reached on Linktr.ee, LinkedIn, YouTube, Facebook, Instagram @montgomeryfertility, and X @MontgomeryF_C.

Dr. Famuyiwa is dedicated to advancing fertility care through research, publications, and educational efforts, including hosting the Fertile Talks podcast. Beyond her clinic, she advocates holistic health and enjoys nature walks. Recognized for her excellence, she is a Castle Connolly Top Doctor and a Women Who Move Maryland honoree. Dr. Famuyiwa’s participation in the Zenith Total Health Expo 2024 reflects her commitment to empowering individuals with knowledge about nutrition, lifestyle, and fertility.

She is the author of “IGF-I and Uterine Growth,” a chapter in the Excerpta Medical International Congress Series, 1997. This work delves into the significant role of Insulin-like Growth Factor I (IGF-I) in uterine development. She also authored “Sex Steroid Regulation of IGF System Gene Expression and Proliferation in Primate Myometrium,” published in the Journal of Clinical Endocrinology and Metabolism in 1996, which explores the regulation of IGF system gene expression by sex steroids and its impact on cellular proliferation in the primate myometrium.